BRIDGEWATER, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate in two panel presentations at the LifeSci Partners 10th Annual Healthcare Corporate Access Event. Panel Presentation Details Title: Dermatology Innovation: Addressing Physician and Patient Underserved Needs Day: Thursday, January 7 Time: 2:00pm Eastern Time Registration Link: https://wsw.com/webcast/lifesci/panel9/2316951     Title: Executing a Successful Product Launch During a Pandemic Day: Friday, January 8 Time: 2:00pm Eastern Time Registration Link: https://wsw.com/webcast/lifesci/panel14/2387307 The format will be a virtual presentation with the opportunity for Q&A at the…

BRIDGEWATER, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate in two panel presentations at the LifeSci Partners 10th Annual Healthcare Corporate Access Event. Panel Presentation Details Title: Dermatology Innovation: Addressing Physician and Patient Underserved Needs Day: Thursday, January 7 Time: 2:00pm Eastern Time Registration Link: https://wsw.com/webcast/lifesci/panel9/2316951     Title: Executing a Successful Product Launch During a Pandemic Day: Friday, January 8 Time: 2:00pm Eastern Time Registration Link: https://wsw.com/webcast/lifesci/panel14/2387307 The format will be a virtual presentation with the opportunity for Q&A at the…

BRIDGEWATER, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) , a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA). The Company, in consultation with the FDA, has established the key elements of the Phase 3 program to support a New Drug Application (NDA) for FCD105 (3% minocycline / 0.3% adapalene foam), the first ever minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris. The End-of-Phase…

BRIDGEWATER, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) , a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA). The Company, in consultation with the FDA, has established the key elements of the Phase 3 program to support a New Drug Application (NDA) for FCD105 (3% minocycline / 0.3% adapalene foam), the first ever minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris. The End-of-Phase…

BRIDGEWATER, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), based on the results of the annual reconstitution of the index announced by Nasdaq on December 11, 2020. The inclusion will become effective prior to the U.S. market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ…

BRIDGEWATER, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), based on the results of the annual reconstitution of the index announced by Nasdaq on December 11, 2020. The inclusion will become effective prior to the U.S. market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ…